本帖最后由 老马 于 2012-1-13 21:20 编辑
# ^0 [" L, U& A3 I/ _* |& A
5 n p3 U4 A+ C+ I$ J: U爱必妥和阿瓦斯丁的比较
; |. ` i+ A" ` O. ^6 p" M
1 L, s6 y6 e0 g1 m1 D& Z3 Z
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/: l5 R2 V' B- O( h5 q `+ R
: g$ e/ p4 u) j; t) y( k( J( o
1 | x. c" e* I# X2 O* H
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/: ^+ F D. _3 ^: `4 o' \
==================================================
3 }! C" X0 C* S$ ?3 tOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)+ W+ C9 H9 ^( D4 w8 r: E ]
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
; N6 E+ J7 ~0 S! X* M$ u3 rResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. B0 \4 g8 m% C3 l6 m
|